Mergers and acquisitions
Actavis’ strong underlying growth and recent strategic acquisitions have positioned the Group among the world’s largest generic pharmaceutical companies.
Acquisition: 90% share in Zhejiang Chiral Medicine Chemicals Company, China
09/04/2008
Price: Financial details not disclosed
Rationale: Chiral is specialized in research, development and production of active pharmaceutical ingredients (APIs). The acquisition is part of Actavis’ strategy to get direct access to low cost API manufacturing.
Acquisition: Pfizer manufacturing site in Nerviano, Italy
31/01/2008
Price: Financial details not disclosed
Rationale: To meet growth projections for injectable oncology (cytotoxic) product portfolio over the coming years. The site also has vial and ampoule manufacturing capability for non-cytotoxic injectable products, which will allow Actavis to expand its hospital product offering.
Acquisition: API division of Sanmar Specialty Chemicals Ltd, India
13/02/2007
Price: Financial details not disclosed
Rationale: Ability to develop and manufacture own active pharmaceutical ingredients
Acquisition: Grandix Pharmaceuticals, India
20/12/2006
Price: Financial details not disclosed
Rationale: Low cost manufacturing capability in India
Acquisition: Abrika Pharmaceuticals Inc., US
30/11/2006
Price: $110 m (plus up to $125 m earn out), 9.5x EV/EBITDA (8.5x with earn out) based on projected 2007 EBITDA.
Rationale: Strong foothold in high value Controlled Release market
Acquisition: ZiO Zdorovje, Russia, 51% holding
21/11/2006
Price: $60 m
Rationale: Enhance prospects in the Russian market and establish a platform for sustainable growth
Acquisition: Sindan, Romania
28/3/2006
Price: $147m, 8.6x EV/EBITDA
Rationale: Entry into the fast growing oncology market
Acquisition: Alpharma human Generics, US
17/10/2005
Price: $810, 9.2x EV/EBITDA
Rationale: Expansion of US and European presence and expansion of product portfolio
Acquisition: Keri Hungary
30/9/2005
Price: Financial details not disclosed
Rationale: Expansion of Central European presence with sales and marketing presence in Hungary
Acquisition: Higia AD, Bulgaria
9/9/2005
Price: Financial details not disclosed
Rationale: Strengthening sales & marketing promotional strategy, control larger part of value chain.
Acquisition: Amide, USA
20/5/2005
Price: $500m (plus $100m earn-out): 8.6x EV/EBITDA
Rationale: Entry into US market
Acquisition: Pharma Avalanche, Czech Republic
22/3/2005
Price: Financial details not disclosed
Rationale: Expansion of Central European presence to Czech Republic and Slovakia
Acquisition: Lotus, India
8/2/2005
Price: €20m
Rationale: Access to lower cost CRO capabilities in India
Acquisition: Biovena, Poland
28/12/2004
Price: Financial details not disclosed
Rationale: Expansion to Central European presence
Acquisition: Pliva Nordic Region
3/2/2004
Price: Financial details not disclosed
Rationale: Expansion of European presence in Nordic market (existing presence in Iceland, Denmark and Sweden)
Acquisition: FAKO, Turkey, 90% holding. Additional 10% acquired in 2006.
19/1/2004
Price: US$63m
Rationale: Access to Turkey and Southern Europe
* When local currency is diverted into EUR, an average rate for that specific year is used.